Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 by Glenmark Pharmaceuticals Limited in respect of Incorporation of a wholly owned subsidiary company "Glenmark Consumer Care Limited"
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has incorporated a new wholly owned subsidiary named 'Glenmark Consumer Care Limited'. The intimation has been filed with the stock exchanges under SEBI's Listing Obligations and Disclosure Requirements (Regulation 30). The subsidiary is fully owned by Glenmark Pharmaceuticals, meaning no outside investors are involved at this stage. The move suggests Glenmark is creating a dedicated entity to house its consumer care business separately from its core pharmaceutical operations. No financial details such as initial capital, valuation, or timelines for operations have been disclosed in this announcement.
This is an early-stage corporate restructuring step with no immediate financial impact on shareholders. Investors should watch for further updates on capital infusion, business transfer, or any potential listing of the new subsidiary, which could unlock value if the consumer care segment is spun off later.